Leustatin (Cladribine)

Cladribine is taken up by lymphocytes and phosphorylated by deoxycytidine kinase to its active triphosphate form. The triphosphate incorporates into DNA during replication, causing strand breaks that trigger apoptosis, leading to selective depletion of malignant B‑cells.

The dosing regimen for Leustatin is determined by the prescribing oncologist based on the patient’s clinical status, disease burden, and laboratory parameters. The prescriber selects the appropriate dose, schedule, and administration route in accordance with approved labeling and local guidelines.

The safety of cladribine during pregnancy and lactation has not been established. It is classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose.

To order Leustatin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Leustatin (cladribine) is a nucleoside analog that offers a short, intensive treatment course with high response rates, whereas alternative agents such as pentostatin require longer infusion schedules. Both target lymphocyte proliferation, but cladribine’s intracellular activation leads to rapid apoptosis, often resulting in durable remissions with fewer treatment cycles.

Leustatin must be stored refrigerated at 2‑8 °C. The vials should be kept in the original packaging, protected from light, and must not be frozen or shaken. Prior to administration, the product should be inspected for particulate matter and used within the time frame specified in the label after removal from refrigeration.

Leustatin is supplied as a sterile solution for subcutaneous injection. A qualified healthcare professional administers the dose by injecting the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique. The injection site should be rotated to minimize local reactions.

The most serious risks include severe immunosuppression leading to opportunistic infections, profound neutropenia, and rare cases of secondary malignancies. Patients should be monitored closely for signs of infection, fever, or hematologic abnormalities, and appropriate prophylactic measures may be required during and after treatment.

Leustatin is contraindicated in patients with known hypersensitivity to cladribine or any excipients, and should be avoided in individuals with active uncontrolled infections, severe hepatic or renal impairment, or in pregnant or breastfeeding women unless the potential benefit outweighs the risk. It should also be used with caution in patients receiving other myelosuppressive therapies.